TherapeuticsMD, Inc.

TXMD

US88338N2062

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:30:00 2024-07-17 EDT			5-day change	1st Jan Change
1.801 ^USD	-3.69%		+2.91%	-19.96%

05-10	TherapeuticsMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-10	TherapeuticsMD, Inc. Continues Evaluation of Strategic Alternatives	CI

TherapeuticsMD, Inc. Receives Approval from U.S. Food and Drug Administration

January 03, 2022 at 06:04 am

TherapeuticsMD, Inc. received approval from U.S. food and drug administration (FDA) on the supplemental new drug application for the 0.5 mg/100 mg dose of the company's BIJUVA product. The company is currently evaluating plans for commercialization of the low dosage BIJUVA product.

Latest news about TherapeuticsMD, Inc.

TherapeuticsMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
TherapeuticsMD, Inc. Continues Evaluation of Strategic Alternatives	05-09	CI
TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Knight Therapeutics Announces Launch of Bijuva in Canada	02-06	MT
Knight Therapeutics Announces Product Launch For IMVEXXY In Canada	01-04	MT
North American Morning Briefing : Stocks Seen Building on CPI Rally; PPI Data Due	11-15	DJ
TherapeuticsMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
TherapeuticsMD, Inc. Announces Evaluation of Strategic Alternatives	11-13	CI
TherapeuticsMD, Inc. Announces Executive Changes	23-08-18	CI
TherapeuticsMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
North American Morning Briefing : Stock Futures -2-	23-08-14	DJ
TherapeuticsMD, Inc. announced that it has received $1.149998 million in funding from Rubric Capital Management LP	23-06-28	CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell 3000E Growth Index	23-06-23	CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell Microcap Index	23-06-23	CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell Microcap Value Index	23-06-23	CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell 3000E Value Index	23-06-23	CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell Microcap Growth Index	23-06-23	CI
TherapeuticsMD, Inc.(NasdaqGS:TXMD) added to Russell 3000E Index	23-06-23	CI
TherapeuticsMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
TherapeuticsMD, Inc. announced that it expects to receive $5 million in funding from Rubric Capital Management LP	23-04-30	CI
TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-07	CI
TherapeuticsMD, Inc. Auditor Raises 'Going Concern' Doubt	23-04-06	CI
North American Morning Briefing : Stocks Seen -2-	23-03-30	DJ
North American Morning Briefing : Traders Reassess -2-	23-03-23	DJ
North American Morning Briefing : Some Calm -2-	23-03-16	DJ

Chart TherapeuticsMD, Inc.

Duration

Period

More charts

Company Profile

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
THERAPEUTICSMD, INC.	-19.96%	21.57M
KYOWA KIRIN CO. LTD.	+33.63%	10.31B
YUHAN CORPORATION	+40.41%	5.23B
SK BIOPHARMACEUTICALS CO., LTD.	-15.24%	4.62B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+11.62%	3.52B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+26.25%	2.31B
BETTA PHARMACEUTICALS CO., LTD.	-38.78%	1.78B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-44.54%	1.69B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
SUPERNUS PHARMACEUTICALS, INC.	+0.03%	1.59B

Specialty & Advanced Pharmaceuticals